Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders

 
• By Jessica Merrill
sickle cell 2
Novo Nordisk is acquiring Forma, investing in sickle cell disease • Source: Shutterstock

More from Deals

More from Business